Company intelligence / Profile preview

贝钰

Zhuhai, Guangdong Province, Chinaitzk.stisa.org.cn ↗

Ownership: Private
Development stage: Other

Overview

Beihai Biotech has developed a proprietary peptide-drug conjugate platform and advanced a robust pipeline of innovative drug candidates targeting major cancers. Its lead asset, BH009 (BEIZRAY), received FDA approval in 2024. The company holds over 40 patents and has multiple programs in clinical development across China and the US

Therapeutic areas: Oncology
Modalities: Peptide-drug conjugateSmall molecule
Industry: Biotech

Beyond the preview

Go deeper on 贝钰.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 贝钰.

Explore the full profile